Evidence map›Paper›PMID 30507785›Full record

ArticlePain2019

Mechanisms underlying mechanical sensitization induced by complement C5a: the roles of macrophages, TRPV1, and calcitonin gene-related peptide receptors.

Charles A Warwick, Leonid P Shutov, Andrew J Shepherd, Durga P Mohapatra, Yuriy M Usachev

Abstract read
In one paragraph

Article in Pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Mitochondrial CaCell calcium · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Peripheral mechanisms of chronic pain.Medical review (2021) · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Charles A WarwickDepartment of Pharmacology, Iowa Neuroscience Institute, University of Iowa, Iowa City, IA, United States.
Leonid P ShutovDepartment of Pharmacology, Iowa Neuroscience Institute, University of Iowa, Iowa City, IA, United States.
Andrew J ShepherdDepartment of Anesthesiology, Washington University Pain Center, Washington University School of Medicine, St. Louis, MO, United States.
Durga P MohapatraDepartment of Anesthesiology, Washington University Pain Center, Washington University School of Medicine, St. Louis, MO, United States.
Yuriy M UsachevDepartment of Pharmacology, Iowa Neuroscience Institute, University of Iowa, Iowa City, IA, United States.
University of Iowa · USWashington University in St. Louis · US

Funding

Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2M
Diabetes Research Training Program Diversity SupplementT32DK112751 · NIDDK · UNIVERSITY OF IOWA · PI Andrew W Norris · 2017 to 2026
$4.8M
Interdisciplinary Training Program in Pain ResearchT32NS045549 · NINDS · UNIVERSITY OF IOWA · PI KATHLEEN A SLUKA, Yuriy M Usachev · 2004 to 2026
$3.7M
Training in Mechanisms and Clinical Presentation of PainT32NS073548 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jami Lynn Saloman, BRADLEY K. TAYLOR · 2012 to 2026
$3.1M
Molecular Mechanisms and Functions of Mitochondrial Ca2+ transport in NeuronsR01NS096246 · NINDS · UNIVERSITY OF IOWA · PI USACHEV, YURIY M · 2016 to 2020
$2.2M
Targeting Mitochondrial Fission for Neuroprotection in Diabetic NeuropathyR01DK116624 · NIDDK · UNIVERSITY OF IOWA · PI STRACK, STEFAN, USACHEV, YURIY M · 2018 to 2021
$2.1M
Mitochondria fission and fusion (MFF)-dependent mechanisms in neuronal toxicityR01NS087068 · NINDS · UNIVERSITY OF IOWA · PI USACHEV, YURIY M · 2014 to 2017
$1.3M
NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R01 DK116624NIDDK NIH HHS T32 DK112751NINDS NIH HHS R01 NS087068NINDS NIH HHS R01 NS096246NINDS NIH HHS T32 NS045549NINDS NIH HHS T32 NS073548
6 · The paper itself

Abstract

The complement system significantly contributes to the development of inflammatory and neuropathic pain, but the underlying mechanisms are poorly understood. Recently, we identified the signaling pathway responsible for thermal hypersensitivity induced by the complement system component C5a. Here, we examine the mechanisms of another important action of C5a, induction of mechanical hypersensitivity. We found that intraplantar injection of C5a produced a dose-dependent mechanical sensitization and that this effect was blocked by chemogenetic ablation of macrophages in both male and female mice. Knockout of TRPV1 or pretreatment with the TRPV1 antagonists, AMG9810 or 5'-iodoresiniferatoxin (5'-IRTX), significantly reduced C5a-induced mechanical sensitization. Notably, local administration of 5'-IRTX 90 minutes after C5a injection resulted in a slow, but complete, reversal of mechanical sensitization, indicating that TRPV1 activity was required for maintaining C5a-induced mechanical hypersensitivity. This slow reversal suggests that neurogenic inflammation and neuropeptide release may be involved. Indeed, pretreatment with a calcitonin gene-related peptide (CGRP) receptor antagonist (but not an antagonist of the neurokinin 1 receptor) prevented C5a-induced mechanical sensitization. Furthermore, intraplantar injection of CGRP produced significant mechanical sensitization in both wild-type and TRPV1 knockout mice. Taken together, these findings suggest that C5a produces mechanical sensitization by initiating macrophage-to-sensory-neuron signaling cascade that involves activation of TRPV1 and CGRP receptor as critical steps in this process.

Indexed as

AcrylamidesAnimalsBridged Bicyclo Compounds, HeterocyclicComplement C5aDipeptidesDisease Models, AnimalDose-Response Relationship, DrugFemaleHyperalgesiaMacrophagesMaleMiceMice, Inbred C57BLNerve Growth FactorPain MeasurementPiperidines1-(N(2)-(3,4-dibromo-N-((4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl)carbonyl)tyrosyl)lysyl)-4-(4-pyridinyl)piperazine3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamideAcrylamidesBridged Bicyclo Compounds, HeterocyclicComplement C5aDipeptidesMaf1 protein, mouseNerve Growth FactorPiperidinesQuinazolinesQuinuclidinesReceptors, Calcitonin Gene-Related PeptideRepressor ProteinsSR 140333TRPA1 Cation ChannelTRPV1 protein, mouseTRPV Cation Channels

Identifiers

PMID30507785
PMCPMC6377341
OpenAlexW2902330933

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.